Additional Data and Key Takeaways in CLL/SLL from EHA 2024

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

The combination of acalabrutinib and venetoclax with or without obinutuzumab improved survival vs standard chemotherapy in patients with previously untreated chronic lymphocytic leukemia.

Mark Geyer, MD, and Yannis K. Valtis, MD, discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.